Oncology
Sacituzumab Tirumotecan Plus Pembrolizumab in PD-L1-Negative Advanced Non-Squamous NSCLC: A Paradigm Shift in First-Line Therapy
Sacituzumab tirumotecan combined with pembrolizumab significantly improves progression-free survival in PD-L1-negative advanced nonsquamous NSCLC compared to chemotherapy plus pembrolizumab, offering a promising new treatment standard with
